Clinical Trial Search

Phase 3 N=1,439 Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Dyslipidemia · Coronary Heart Disease · Mixed Dyslipidemia

Primary: Mean Percent Change in Triglycerides From Baseline to Final Visit — -47.1; -42.9; -32.6; -24.4 percent change — p=<0.001

Abbott Results Mar 2009 View details

Phase 3 N=609 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Mixed Dyslipidemia · Coronary Heart Disease · Dyslipidemia

Primary: Mean Percent Change in Triglycerides From Baseline to Final Visit — -45.6; -42.1; -29.6; -16.5 percent change — p=<0.001

Abbott Results Mar 2009 View details

Phase 3 N=650 Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Dyslipidemia · Coronary Heart Disease · Mixed Dyslipidemia

Primary: Mean Percent Change in Triglycerides From Baseline to Final Visit — -37.4; -42.7; -31.7; -14.2 percent change — p=<0.001

Abbott Results Mar 2009 View details

Phase 3 N=504 A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression

Bipolar Disorder

Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score — -6.07; -7.66; -5.75; -10.12 score on scale — p=0.6409

Pfizer's Upjohn has merged with Mylan to form… Results Mar 2009 View details

Phase 3 N=204 A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Invasive Candidiasis

Primary: Number of Patients Who Develop Significant Drug-related Adverse Events. — 2; 3 Participants

Merck Sharp & Dohme LLC Results Mar 2009 View details

Phase 3 N=908 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

Primary: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median — 17.0; 45.7; 52.7 percentage of days…

Takeda Results Mar 2009 View details

Phase 3 N=220 Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

Peripheral Neuropathy · HIV Infections

Primary: Mean Visual Analogue Scale (VAS) Pain Scores — 38.61; 30.75; 30.16; 28.95 score on scale

Pfizer's Upjohn has merged with Mylan to form… Results Mar 2009 View details

Phase 3 N=2,054 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Reflux · Esophagitis, Peptic

Primary: Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis. — 86.9; 89.4; 84.6 percentage of subjects…

Takeda Results Mar 2009 0.5% serious AE View details

Phase 3 N=90 A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Primary: The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4 — 11; 6; 3 Particpants

Abbott Results Mar 2009 View details

Phase 3 N=2,038 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Reflux · Esophagitis, Peptic

Primary: Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis. — 85.3; 85.8; 79.0 Percentage of…

Takeda Results Mar 2009 0.6% serious AE View details

Phase 3 N=947 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Primary: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median — 18.5; 54.9; 50.0 percentage of days…

Takeda Results Mar 2009 View details

Phase 3 N=908 Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

Primary: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median — 17.0; 45.7; 52.7 percentage of days…

Takeda Results Mar 2009 View details

Phase 3 N=318 A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

Congestive Heart Failure

Primary: Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography — -18.36; -20.81 mL/m^2

CTI-1, LLC Results Mar 2009 View details

Phase 3 N=200 A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.

Infections, Rotavirus

Primary: Presence of Rotavirus Vaccine Strain in Any Stool Sample From Twin Receiving Placebo. — 15 subjects

GlaxoSmithKline Results Mar 2009 5.5% serious AE View details

Phase 3 N=357 This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia

Fibromyalgia

Primary: Change From Baseline to Week 4 in Pain Visual Analog Scale (VAS) Score — -18.1 mm

Pfizer's Upjohn has merged with Mylan to form… Results Mar 2009 View details